Molecular Studies of Peptide Assemblies and Related Applications in Tumor Therapy and Diagnosis

2020 ◽  
pp. 255-286
Author(s):  
Huayi Wang ◽  
Xiaocui Fang ◽  
Yanlian Yang ◽  
Chen Wang
Keyword(s):  
Tumor Therapy ◽  
Molecular Studies ◽  
Therapy And Diagnosis

A Triple-responsive Targeted Hybrid Liposomes with High MRI Performance for Tumor Diagnosis and Therapy

2021 ◽  
Author(s):  
Weihe Yao ◽  
Chenyu Liu ◽  
Ning Wang ◽  
Hengjun Zhou ◽  
Hailiang Chen ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Tumor Therapy ◽  
Delivery Systems ◽  
Tumor Diagnosis ◽  
Diagnosis And Therapy ◽  
Promising Strategy ◽  
Therapy And Diagnosis

The targeted multi-responsive drug delivery systems with MRI capacity were anticipated as a promising strategy for tumor therapy and diagnosis. Herein, we successfully synthesized anisamide-modified and non-modified UV/GSH-responsive molecules (10,10-NB-S-S-P-AA...

Recent advances in microneedles for tumor therapy and diagnosis

2021 ◽  
Vol 23 ◽  
pp. 101036
Author(s):  
Shiyang Lin ◽  
Yi Cao ◽  
Jiajie Chen ◽  
Zhengfang Tian ◽  
Yufang Zhu
Keyword(s):  
Tumor Therapy ◽  
Recent Advances ◽  
Therapy And Diagnosis

Polymeric Matrix-Based Nanoplatforms toward Tumor Therapy and Diagnosis

2021 ◽  
pp. 21-48
Author(s):  
Houjuan Zhu ◽  
Xian Jun Loh ◽  
Enyi Ye ◽  
Zibiao Li
Keyword(s):  
Tumor Therapy ◽  
Polymeric Matrix ◽  
Therapy And Diagnosis

Enzyme-assisted Cell Photosensitization: A Proposal for an Efficient Approach to Tumor Therapy and Diagnosis. The Rose Bengal Fluorogenic Substrate

1997 ◽  
Vol 66 (3) ◽  
pp. 374-383 ◽  
Author(s):  
G. Bottiroli ◽  
A. C. Croce ◽  
P. Balzarini ◽  
D. Locatelli ◽  
P. Baglioni ◽  
...  
Keyword(s):  
Rose Bengal ◽  
Tumor Therapy ◽  
Fluorogenic Substrate ◽  
Efficient Approach ◽  
Therapy And Diagnosis ◽  
The Rose

scholarly journals Targeted Radiotherapeutics from 'Bench-to-Bedside'

2020 ◽  
Vol 74 (12) ◽  
pp. 939-945
Author(s):  
Cristina Müller ◽  
Martin Béhé ◽  
Susanne Geistlich ◽  
Nicholas P. van der Meulen ◽  
Roger Schibli
Keyword(s):  
Tumor Therapy ◽  
Nuclear Imaging ◽  
High Energy ◽  
Biological Molecules ◽  
Decay Properties ◽  
Research Activities ◽  
Efficient Delivery ◽  
Paul Scherrer ◽  
Therapy And Diagnosis ◽  
Selection Of

The concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to disseminated cancer lesions while minimizing damage to healthy tissue and organs. Critical aspects for successful development of novel radiopharmaceuticals for TRT are: i) the identification and characterization of suitable targets expressed on cancer cells; ii) the selection of chemical or biological molecules which exhibit high affinity and selectivity for the cancer cell-associated target; iii) the selection of a radionuclide with decay properties that suit the properties of the targeting molecule and the clinical purpose. The Center for Radiopharmaceutical Sciences (CRS) at the Paul Scherrer Institute in Switzerland is privileged to be situated close to unique infrastructure for radionuclide production (high energy accelerators and a neutron source) and access to C/B-type laboratories including preclinical, nuclear imaging equipment and Swissmedic-certified laboratories for the preparation of drug samples for human use. These favorable circumstances allow production of non-standard radionuclides, exploring their biochemical and pharmacological features and effects for tumor therapy and diagnosis, while investigating and characterizing new targeting structures and optimizing these aspects for translational research on radiopharmaceuticals. In close collaboration with various clinical partners in Switzerland, the most promising candidates are translated to clinics for 'first-in-human' studies. This article gives an overview of the research activities at CRS in the field of TRT by the presentation of a few selected projects.

scholarly journals A “Double-Locked” and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy

Molecules ◽  
2022 ◽  
Vol 27 (2) ◽  
pp. 425
Author(s):  
Jia Luo ◽  
Zongyu Guan ◽  
Weijie Gao ◽  
Chen Wang ◽  
Zhongyuan Xu ◽  
...  
Keyword(s):  
Tumor Imaging ◽  
Tumor Therapy ◽  
Tumor Resection ◽  
Acid Group ◽  
Inhibitory Effect ◽  
Theranostic Agent ◽  
Precise Diagnosis ◽  
Group A ◽  
Theranostic Agents ◽  
Therapy And Diagnosis

Theranostic agents for concurrent cancer therapy and diagnosis have begun attracting attention as a promising modality. However, accurate imaging and identification remains a great challenge for theranostic agents. Here, we designed and synthesized a novel theranostic agent H6M based on the “double-locked” strategy by introducing an electron-withdrawing nitro group into 1-position of a pH-responsive 3-amino-β-carboline and further covalently linking the hydroxamic acid group, a zinc-binding group (ZBG), to the 3-position of β-carboline to obtain histone deacetylase (HDAC) inhibitory effect for combined HDAC-targeted therapy. We found that H6M can be specifically reduced under overexpressed nitroreductase (NTR) to produce H6AQ, which emits bright fluorescence at low pH. Notably, H6M demonstrated a selective fluorescence imaging via successive reactions with NTR (first “key”) and pH (second “key”), and precisely identified tumor margins with a high S/N ratio to guide tumor resection. Finally, H6M exerted robust HDAC1/cancer cell inhibitory activities compared with a known HDAC inhibitor SAHA. Therefore, the NTR/pH-activated theranostic agent provided a novel tool for precise diagnosis and efficient tumor therapy.

Rapamycin-regulated Control of Antiangiogenic Tumor Therapy Following rAAV-mediated Gene Transfer

2007 ◽  
Author(s):  
Minh Nguyen ◽  
Guang Huan-Tu ◽  
Melissa Gonzalez-Edick ◽  
Victor M Rivera ◽  
Tim Clackson ◽  
...  
Keyword(s):  
Gene Transfer ◽  
Tumor Therapy

Darwin's two competing phylogenetic trees: marsupials as ancestors or sister taxa?

2012 ◽  
Vol 39 (2) ◽  
pp. 217-233 ◽  
Author(s):  
J. David Archibald
Keyword(s):  
Fossil Record ◽  
Evolutionary Biology ◽  
Phylogenetic Trees ◽  
Charles Darwin ◽  
The Other ◽  
Charles Lyell ◽  
Single Origin ◽  
Molecular Studies ◽  
Richard Owen ◽  
First Time

Studies of the origin and diversification of major groups of plants and animals are contentious topics in current evolutionary biology. This includes the study of the timing and relationships of the two major clades of extant mammals – marsupials and placentals. Molecular studies concerned with marsupial and placental origin and diversification can be at odds with the fossil record. Such studies are, however, not a recent phenomenon. Over 150 years ago Charles Darwin weighed two alternative views on the origin of marsupials and placentals. Less than a year after the publication of On the origin of species, Darwin outlined these in a letter to Charles Lyell dated 23 September 1860. The letter concluded with two competing phylogenetic diagrams. One showed marsupials as ancestral to both living marsupials and placentals, whereas the other showed a non-marsupial, non-placental as being ancestral to both living marsupials and placentals. These two diagrams are published here for the first time. These are the only such competing phylogenetic diagrams that Darwin is known to have produced. In addition to examining the question of mammalian origins in this letter and in other manuscript notes discussed here, Darwin confronted the broader issue as to whether major groups of animals had a single origin (monophyly) or were the result of “continuous creation” as advocated for some groups by Richard Owen. Charles Lyell had held similar views to those of Owen, but it is clear from correspondence with Darwin that he was beginning to accept the idea of monophyly of major groups.

Kruppel-Like Factor 4: From Physiological Functions to Tumor Therapy

2016 ◽  
Vol 7 (1-2) ◽  
pp. 153-158
Author(s):  
Ruocong Zhao ◽  
Yunxin Lai ◽  
Peng Li
Keyword(s):  
Tumor Therapy ◽  
Physiological Functions
Sign in / Sign up

Export Citation Format

Share Document